How Has The Opioid Use Disorder (OUD) Market Size Evolved Historically?
The opioid use disorder (oud) market has seen considerable growth due to a variety of factors.
•The market for opioid use disorder (OUD) has undergone swift expansion in recent years. The predicted growth shows an increase from $3.96 billion in 2024 to $4.39 billion in 2025, with an expected compound annual growth rate (CAGR) of 10.9%.
Factors contributing to this growth during the historic period include higher prescription rates, evolving practices in pain management, advancements in drug advertising, and the stigma associated with addiction.
What Will Be The Opioid Use Disorder (OUD) Market Size In The Future?
The opioid use disorder (oud) market is expected to maintain its strong growth trajectory in upcoming years.
• The market for opioid use disorder (OUD) is projected to experience considerable expansion in the upcoming years, growing to $6.94 billion by 2029 with a compound annual growth rate (CAGR) of 12.1%.
This predicted growth throughout the forecast period can be linked to several factors such as regulatory measures, a focus on alternative methods for pain management, increased access to treatment, and public health campaigns. Key trends expected to rise during the forecast period include advancement in treatment technology, personalized treatment strategies, holistic care models, community-supported programs, and emphasis on early intervention and prevention.
What Are The Primary Growth Drivers In The Opioid Use Disorder (OUD) Market?
The opioid use disorder (OUD) market is predicted to expand as the number of opioids addiction instances continues to grow. Opioid addiction is a medical condition marked by compulsive, chronic opioid use that adversely impacts the body. Continued opioid use, which can provide a sense of elation and alleviate pain, could lead to tolerance development, necessitating higher doses to retain the same effect and potentially leading to opioid use disorder. As an example, the Centers for Disease Control and Prevention, a US-based public health agency, reported in March 2024 that the synthetic opioid drug overdose rate climbed 4.1%, escalating from 21.8 to 22.7 between 2021 and 2022. Hence, the upswing in opioid addiction cases is a driving factor for the expansion of the opioid use disorder (OUD) market.
What Is The Segmentation Of The Global Opioid Use Disorder (OUD) Market?
The opioid use disorder (OUD) market covered in this report is segmented –
1) By Drug Type: Buprenorphine, Naltrexone, Methadone
2) By Route of Administration: Oral, Parenteral
3) By Age Group: 19 To 40, 41 To 60, 61 And Over
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Stores, Online Pharmacies
Subsegments:
1) By Buprenorphine: Suboxone, Buprenorphine Tablets, Buprenorphine Film
2) By Naltrexone: Naltrexone Tablets, Vivitrol
3) By Methadone: Methadone Tablets, Methadone Oral Solution
Pre-Book The Opioid Use Disorder (OUD) Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Opioid Use Disorder (OUD) Market Landscape?
The key trend gaining traction in the opioid use disorder (OUD) market is product innovation. Leading companies in the OUD market are creating novel products to maintain their market stance. For example, in May 2023, Brixadi (buprenorphine) extended-release injection was approved by the U.S. Food and Drug Administration, a federal agency based in the US, for the treatment of moderate to severe OUD. Brixadi comes in two different dosage forms: a weekly injection for patients who have started treatment with a single dose of a transmucosal buprenorphine product or are currently on the medication, and a monthly version for those who are already using the medication.
Who Are the Key Players in the Opioid Use Disorder (OUD) Market?
Major companies operating in the opioid use disorder (OUD) market include:
• Pfizer Inc.
• Novartis AG
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Chiesi Pharmaceuticals S.p.A.
• Hikma Pharmaceuticals Plc.
• Mallinckrodt Pharmaceuticals
• Indivior Plc.
• Purdue Pharma L.P
• Alkermes Inc.
• Collegium Pharmaceutical Inc.
• Vanda Pharmaceuticals Inc.
• Camurus AB
• Tris Pharma Inc.
• Mylan NV.
• Orexo US Inc.
• Zogenix Inc.
• Rhodes Pharmaceuticals L.P.
• Omeros Corporation
• Braeburn Pharmaceuticals Inc.
• Adapt Pharma Inc.
• Titan Pharmaceuticals Inc.
• BioDelivery Sciences International Inc.
• AcelRx Pharmaceuticals Inc.
• KemPharm Inc.
What are the Regional Insights into the Opioid Use Disorder (OUD) Market?
North America was the largest region in the opioid use disorder (OUD) market in 2024. The regions covered in the opioid use disorder (OUD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
